Arkolith/Insider Trading/ENSC/Form 4

Kirkpatrick Lynn

Chief Executive Officer, DirectorEnsysce Biosciences, Inc. (ENSC) · full profile →Form 4 · filed May 27, 2022
Net Buying
Open-Market Buys
$49K
Open-Market Sells
$0
Net Open-Market Flow
$49K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 26, 2022Buy(P)27K$0.53$14K382K
May 25, 2022Buy(P)70K$0.49$34K355K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 17, 2022Grant(A)200K——2.5M

Transaction Codes

P
Open-market purchase
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001493152-22-015294) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML